Latest Medical Devices News

Page 3 of 67
Cyclopharm has reported record third-quarter US Technegas revenue of A$1.62 million, with 76% generated by recurring consumable orders. Its installed base and hospital pipeline expanded sharply after new clinical guidelines preferred Technegas when available, while quarterly cash burn fell to A$0.9 million.
Ada Torres
Ada Torres
29 Oct 2026
Atomo Diagnostics has signed an MOU with Innovation Scientific to develop a fourth-generation HIV rapid test using its Galileo cassette. The project could add a new product to Atomo’s pipeline, but regulatory approval, clinical work and definitive commercial agreements remain outstanding.
Ada Torres
Ada Torres
29 Oct 2026
Saluda Medical delivered a strong operational start to FY27, with US implants up 55% and quarterly revenue rising 26% to US$23.1 million. But the medical device company ended September with US$73.6 million in cash, US$100 million of secured debt drawn and estimated funding for just 2.3 quarters at the quarter’s cash-use rate.
Ada Torres
Ada Torres
29 Oct 2026
Resonance Health has reported encouraging preliminary results from an investigational MRI software device that identifies liver fibrosis without additional scanner hardware. The early data are promising, but the model remains unverified and regulatory clearance is still ahead.
Ada Torres
Ada Torres
28 Oct 2026
Epiminder says its $65.1 million cash balance can fund the DETECT study and next-generation Minder device into 2028, despite a higher quarterly operating outflow. The company also paid $3.5 million to major shareholder Cochlear for research and development during the quarter.
Ada Torres
Ada Torres
28 Oct 2026
Vitrafy has expanded its US blood and cell therapy partnerships while preparing Guardion for a planned medical device listing by the end of 2026. The company ended September with A$38.3 million in cash and term deposits, but expects spending to rise as validation and manufacturing accelerate.
Victor Sage
Victor Sage
28 Oct 2026
OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
Victor Sage
27 Oct 2026
ReNerve has reported its strongest quarter yet, with sales climbing to $584,000 as the medical device company expands across Asia-Pacific. The growth came alongside a secured funding drawdown, leaving the company with $1.62 million in cash but continued negative operating cash flow.
Victor Sage
Victor Sage
26 Oct 2026
EMVision Medical Devices has taken its pivotal emu™ trial beyond 230 participants while preparing to add acute ischaemic stroke detection to the FDA validation program. The ASX-listed medtech ended September with $18.1 million in cash and $3.7 million in remaining grant funding.
Victor Sage
Victor Sage
26 Oct 2026
Echo IQ’s FDA-cleared EchoSolv AS platform processed 9,697 full-result assessments in the September quarter, while the company ended the period with A$107.8 million in cash. The stronger balance sheet gives it room to pursue US enterprise deployments, but commercial conversion and the unresolved EchoSolv HF regulatory pathway remain the key tests.
Victor Sage
Victor Sage
26 Oct 2026
Saluda Medical delivered 28% FY26 revenue growth and expanded its spinal cord stimulation opportunity with CAP24, but its annual report warns that additional capital may be needed within 12 months. The ASX-listed medical device company also begins FY27 under new CEO Michael Mathias.
Victor Sage
Victor Sage
23 Oct 2026
BluGlass has expanded its customer-funded GaN laser programs with a A$1.4 million Uviquity contract and a new A$286,000 photonics collaboration. But its A$8 million facility is fully drawn, carries 16.5% interest and leaves reported funding coverage at 2.8 quarters.
Victor Sage
Victor Sage
23 Oct 2026

Browse the archive

Full archive